The Fly | TalkMarkets | Page 142
Real-Time Financial News
Contributor's Links: TheFly.com
The Fly is a leading digital publisher of real-time financial news. Our financial market experts understand that news impacting stock prices can originate from anywhere, at any time. The Fly team scours all sources of company news, from mainstream to cutting-edge, ...more

Articles

Latest Posts
2257 to 2272 of 4127 Posts
<<< 1 ... 140 141 142 143 144 ... 258 >>>
Berenberg Says Model 3 Margin Target 'Not Hype,' Boosts Tesla Target To $500
Investors have largely dismissed the prospect of 25% gross margin on Tesla's Model 3 amid production bottlenecks and quality issues, Berenberg analyst Alexander Haissl tells investors in a research note.
Dollar Tree Could Hit 'Home Run' By Charging Over $1, Analyst Says
Shares of Dollar Tree are in focus after a Wells Fargo analyst said the company could unlock value by changing its pricing strategy.
Loxo Gains, Jounce Plunges After Cancer Meeting Abstracts Released
Shares of Loxo Oncology jumped in after the biotech company released data in abstracts in anticipation of the 2018 American Society of Clinical Oncology Annual Meeting that is being held June 1-5 in Chicago.
Spotify Drops After YouTube Unveils New Music Streaming Service YouTube Music
Shares of Spotify are down after Google confirmed Wednesday night that it will launch a new music streaming service, YouTube Music, next week. Despite the launch of a rival offering, an analyst contended that Spotify is still "best in class."
GameStop In Focus After Tiger Agitates For Strategic Review
Shares of GameStop are in focus on Wednesday after a hedge fund sent a letter to the game retailer's board calling on it to conduct a strategic review amid recent management reshuffling.
Zoetis To Acquire Abaxis For $83 Per Share, Or Approximately $2B In Aggregate
Zoetis Inc. and Abaxis, Inc. announced a definitive merger agreement pursuant to which Zoetis will acquire Abaxis for $83 per share in cash, or approximately $2B in aggregate.
Analysts Losing Faith On CBS, Viacom Merger Amid Lawsuit Against Parent Company
This morning, Bernstein analyst Todd Juenger upgraded CBS to Outperform and said he views the probability of a CBS-Viacom re-merger as close to zero for many years to come.
Piper Downgrades Ford For Not Keeping Up As Robo-Taxis Promise Fundamental Shift
While pointing out that General Motors is his favorite way to invest in this theme, the analyst downgraded Ford to Neutral as he believes the company may have advantages in the autonomous vehicle segment but is not a leader in this market.
Yelp Slides As Investors Wary Of New Advertising Platform, Competition
Yelp which publishes crowd-sourced reviews about local businesses and has an online reservation service, has been struggling since reporting quarterly earnings last Thursday evening.
Xerox Falls After Terminating Deal With Fujifilm Under Activists' Pressure
Shares of Xerox Corp. are falling after the company announced the termination of its deal with Fujifilm and a new settlement agreement with billionaire investors Carl Icahn and Darwin Deason.
Acacia, Oclaro Rise After Trump Extends Olive Branch To China's ZTE
Shares of Acacia Communications and Oclaro, both suppliers to ZTE Corp. are on the rise after President Donald Trump tweeted that he was working to give the Chinese tech company a "way to get back into business."
Cadence Bancorp To Merge With State Bank Financial
Cadence Bancorp and State Bank Financial jointly announced entry into a definitive merger agreement in a stock-for-stock transaction, creating a combination with $16B in assets, $12B in loans, $13B in deposits and approximately 100 branches.
GameStop Slips After CEO Resigns Only Months After Taking Top Post
Shares of GameStop were trading lower after its chief executive officer resigned from the position for personal reasons, effective immediately.
After Meeting With CEO, JPMorgan Upgrades Verizon To Overweight
JPMorgan analyst Philip Cusick upgraded Verizon Communications to Overweight from Neutral with an unchanged price target of $58.
Exelixis, Roche Slide After Colon Cancer Drug Fails To Meet Primary Study Goal
Shares of Exelixis and partner Roche are under pressure this morning after the companies announced that the Phase 3 IMblaze370 trial did not achieve statistical-significance on the primary efficacy endpoint.
JPMorgan Upgrades First Solar To Overweight With $85 Price Target
JPMorgan analyst Paul Coster upgraded First Solar to Overweight from Neutral and raised his price target for the shares to $85 from $74.
2257 to 2272 of 4127 Posts
<<< 1 ... 140 141 142 143 144 ... 258 >>>